This study provides valuable guidance for doctors and patients when choosing diabetes medications. It confirms that ...

Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper versions of biologics such as Humira and Stelara.

Jefferies backs Lupin, Zydus, and Biocon amid shifting US pharma market shares. Discover why these stocks are set to shine.

1 Two insulin glargine biosimilars, Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr), were previously approved, making Merilog the third overall insulin biosimilar to be greenlit ...

(a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee (R) (insulin glargine-yfgn injection) as the first interchangeable biosimilar ...

1 Merilog is the third overall insulin biosimilar to receive approval, following 2 insulin glargine biosimilars: Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr). 2 “The FDA has ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...